A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.
Inclusion Criteria:
Exclusion Criteria:
Caba, Buenos Aires C1408INH, Argentina
Caba, Buenos Aires C1416DRJ, Argentina
Caba, Buenos Aires C1425AST, Argentina
Longueil, Quebec J4N 1L6, Canada
Ste-Foy, Quebec G1V 4G2, Canada
Vaerloese, DK-3500, Denmark
Murs ErignƩ, 49610, France
NyiregyhƔza, 4400, Hungary
Daugavplis, LV-5417, Latvia
S.-Petersburg, 191187, Russia
S.-Petersburg, 196247, Russia
Hospitalet de Llbregat, 08902, Spain
Taichung County, Taiwan